Pfizer Virus Vaccine On Track For October Regulatory Review

Pfizer (PFE) – Get report and its German partner BioNTech (BNTX) – Get report were increased in premarth trade Friday after the companies said their Covid-19 vaccine candidate would pass tests in the final stage.

The companies said the vaccine was “well tolerated with mild to moderate fever in less than 20% of participants.”

Pfizer and BioNTech said last Thursday that they are continuing to analyze data from Phase 1 trials in the US and Germany.

“The full body of clinical and preclinical data informs Pfizer and BioNTech’s decision to select BNT162b2 as the lead candidate to continue in pivotal trials,” said Kathrin U. Jansen, senior vice president of Pfizer and head of fax research and development .